Results of rituximab retreatment in 11 patients
| Patient no./sex (M/F) age (y) . | ITP duration (y) . | RTX regimen . | Results of first RTX course/duration (mo) . | Date of second RTX course . | Results of second RTX course/duration (mo) . | Date of third RTX course (mo) . | Results of third RTX course/duration (mo) . | Date of fourth RTX course . | Results of fourth RTX course/duration (mo) . |
|---|---|---|---|---|---|---|---|---|---|
| 1/M 53 | 17 | STD | R/6 | Month 12 | Sustained* RC/12 | ||||
| 2/F 80 | 2.3 | STD | CR/6 | Month 12 | CR/16/relapse | Month 30 | Sustained* CR/12 | ||
| 3/F 51 | 9.6 | STD | CR/6 | Month 18 | Sustained* CR/23 | ||||
| 4/F 47 | 9.4 | STD | Failure | Month 18 | Failure | ||||
| 5/F 71 | 3.4 | STD | CR/14 | Month 18 | CR/12/relapse | Month 30 | CR/2/relapse | Month 36 | CR/7/relapse |
| 6/F 56 | 13.2 | RA | CR/24 | Month 36 | R/3/relapse | ||||
| 7/ M 38 | 16.9 | RA | R/12 | Month 24 | Not evaluable† | ||||
| 8/F 33 | 4.7 | RA | CR/23 | Month 42 | Not evaluable‡ | ||||
| 9/F 45 | 0.17 | STD | CR/13 | Month 24 | Sustained* CR/9 | ||||
| 10/F 65 | 0.9 | RA | CR/23 | Month 23 | Sustained* CR/4 | ||||
| 11/M 37 | 23.9 | STD | CR/36 | Month 42 | Sustained* CR/2 |
| Patient no./sex (M/F) age (y) . | ITP duration (y) . | RTX regimen . | Results of first RTX course/duration (mo) . | Date of second RTX course . | Results of second RTX course/duration (mo) . | Date of third RTX course (mo) . | Results of third RTX course/duration (mo) . | Date of fourth RTX course . | Results of fourth RTX course/duration (mo) . |
|---|---|---|---|---|---|---|---|---|---|
| 1/M 53 | 17 | STD | R/6 | Month 12 | Sustained* RC/12 | ||||
| 2/F 80 | 2.3 | STD | CR/6 | Month 12 | CR/16/relapse | Month 30 | Sustained* CR/12 | ||
| 3/F 51 | 9.6 | STD | CR/6 | Month 18 | Sustained* CR/23 | ||||
| 4/F 47 | 9.4 | STD | Failure | Month 18 | Failure | ||||
| 5/F 71 | 3.4 | STD | CR/14 | Month 18 | CR/12/relapse | Month 30 | CR/2/relapse | Month 36 | CR/7/relapse |
| 6/F 56 | 13.2 | RA | CR/24 | Month 36 | R/3/relapse | ||||
| 7/ M 38 | 16.9 | RA | R/12 | Month 24 | Not evaluable† | ||||
| 8/F 33 | 4.7 | RA | CR/23 | Month 42 | Not evaluable‡ | ||||
| 9/F 45 | 0.17 | STD | CR/13 | Month 24 | Sustained* CR/9 | ||||
| 10/F 65 | 0.9 | RA | CR/23 | Month 23 | Sustained* CR/4 | ||||
| 11/M 37 | 23.9 | STD | CR/36 | Month 42 | Sustained* CR/2 |
RA, “rheumatoid arthritis regimen” for rituximab infusions (ie, 2 fixed 1-g infusions 2 wk apart); RTX, rituximab; STD, “standard regimen” for rituximab infusions (ie, 4 weekly infusions of 375 mg/m2).
Patient was always in remission at the last follow-up.
Patient 7 was not evaluable because a new course of rituximab was associated with treatment with a thrombopoietin agonist.
Patient 8 was not evaluable because of being lost to follow-up immediately after rituximab infusions.